NCT01237951 · OUTCOME

Percent of Participants Dying From Treatment-Related Complications

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma · Source last updated 2020-05-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From date of transplant until the date of death from treatment-related complications, assessed up to 2 years

What was measured

Participants who died from treatment-related complications from the time of ASCT.

Patients with refractory or relapsed myeloma received high-dose GemBuMel with ASCT

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Gemcitabine/Busulfan/Melphalan	74

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Gemcitabine/Busulfan/Melphalan	4	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Participants who died from treatment-related complications from the time of ASCT.

groups

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

From date of transplant until the date of death from treatment-related complications, assessed up to 2 years

title

Percent of Participants Dying From Treatment-Related Complications

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice